Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

BACKGROUND: Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Paton, Nicholas I, Kityo, Cissy, Thompson, Jennifer, Nankya, Immaculate, Bagenda, Leonard, Hoppe, Anne, Hakim, James, Kambugu, Andrew, van Oosterhout, Joep J, Kiconco, Mary, Bertagnolio, Silvia, Easterbrook, Philippa J, Mugyenyi, Peter, Walker, A Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555436/
https://www.ncbi.nlm.nih.gov/pubmed/28495562
http://dx.doi.org/10.1016/S2352-3018(17)30065-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555436/
https://www.ncbi.nlm.nih.gov/pubmed/28495562
http://dx.doi.org/10.1016/S2352-3018(17)30065-6

Ejemplares similares